According to research at the University of Munich, Germany,
stress and motion sickness in humans are associated with
impaired endocannabinoid activity. They concluded that enhancing
endocannabinoid signalling "may represent an alternative
therapeutic strategy for motion sickness in individuals who do not
respond to currently available treatments." (Source: Choukèr A, et
al. PLoS One 2010;5(5):e10752.)